BioTissue

Bio-Tissue, a subsidiary of TissueTech, specializes in regenerative medicine focused on ocular surface diseases and surgical wound care. The company leverages the natural properties of human amniotic membrane tissue to promote wound healing, reduce scar formation, and control inflammation. Bio-Tissue's core products, PROKERA and AmnioGraft, are designed to support reepithelialization and improve clinical outcomes for patients. The company serves healthcare professionals, including ophthalmologists and surgeons, by providing evidence-based, FDA-recognized solutions that enhance patient satisfaction and practice growth. Operating in the ocular, surgical wound, and pain management markets, Bio-Tissue generates revenue through the sale of its specialized medical products. The business model focuses on fostering trust and delivering sustainable health economic value by addressing unmet clinical needs with differentiated solutions.

Keywords: regenerative medicine, ocular surface, amniotic membrane, wound healing, PROKERA, AmnioGraft, inflammation control, scar reduction, FDA-recognized, healthcare professionals.